Found: 108
Select item for more details and to access through your institution.
Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis.
- Published in:
- JAMA Dermatology, 2024, v. 160, n. 1, p. 71, doi. 10.1001/jamadermatol.2023.4846
- By:
- Publication type:
- Article
Biosimilars for the Treatment of Psoriasis: A Systematic Review of Clinical Trials and Observational Studies.
- Published in:
- JAMA Dermatology, 2023, v. 159, n. 7, p. 763, doi. 10.1001/jamadermatol.2023.1338
- By:
- Publication type:
- Article
Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.
- Published in:
- 2022
- By:
- Publication type:
- journal article
International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Correction to: OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target.
- Published in:
- American Journal of Clinical Dermatology, 2024, v. 25, n. 3, p. 447, doi. 10.1007/s40257-023-00838-9
- By:
- Publication type:
- Article
Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial.
- Published in:
- American Journal of Clinical Dermatology, 2024, v. 25, n. 2, p. 315, doi. 10.1007/s40257-023-00816-1
- By:
- Publication type:
- Article
Clinical Disease Measures in Generalized Pustular Psoriasis.
- Published in:
- American Journal of Clinical Dermatology, 2022, v. 23, n. 1, p. 39, doi. 10.1007/s40257-021-00653-0
- By:
- Publication type:
- Article
Progress to Date in Advancing Stratified Medicine in Psoriasis.
- Published in:
- American Journal of Clinical Dermatology, 2020, v. 21, n. 5, p. 619, doi. 10.1007/s40257-020-00533-z
- By:
- Publication type:
- Article
Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council.
- Published in:
- American Journal of Clinical Dermatology, 2019, v. 20, n. 5, p. 699, doi. 10.1007/s40257-019-00458-2
- By:
- Publication type:
- Article
Mapping DNA interaction landscapes in psoriasis susceptibility loci highlights KLF4 as a target gene in 9q31.
- Published in:
- BMC Biology, 2020, v. 18, n. 1, p. 1, doi. 10.1186/s12915-020-00779-3
- By:
- Publication type:
- Article
Author Correction: Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-25066-9
- By:
- Publication type:
- Article
A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Correction: Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 10, p. 2841, doi. 10.1007/s13555-024-01261-6
- By:
- Publication type:
- Article
Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 9, p. 2539, doi. 10.1007/s13555-024-01245-6
- By:
- Publication type:
- Article
Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2077, doi. 10.1007/s13555-024-01210-3
- By:
- Publication type:
- Article
Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 11, p. 2839, doi. 10.1007/s13555-023-01034-7
- By:
- Publication type:
- Article
Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 12, p. 3031, doi. 10.1007/s13555-023-01054-3
- By:
- Publication type:
- Article
Elevating the Standard of Care for Patients with Psoriasis: 'Calls to Action' from Epicensus, a Multistakeholder Pan-European Initiative.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 1, p. 245, doi. 10.1007/s13555-022-00846-3
- By:
- Publication type:
- Article
Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 8, p. 1777, doi. 10.1007/s13555-022-00760-8
- By:
- Publication type:
- Article
A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 3, p. 787, doi. 10.1007/s13555-022-00687-0
- By:
- Publication type:
- Article
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 2, p. 561, doi. 10.1007/s13555-021-00679-6
- By:
- Publication type:
- Article
Long-Term Proactive Treatment of Plaque Psoriasis with Calcipotriene/Betamethasone Dipropionate Foam Prolongs Remission and Reduces Relapses Irrespective of Patient Baseline Characteristics.
- Published in:
- Dermatology & Therapy, 2021, v. 11, n. 5, p. 1657, doi. 10.1007/s13555-021-00585-x
- By:
- Publication type:
- Article
Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 Trials.
- Published in:
- Dermatology & Therapy, 2021, v. 11, n. 5, p. 1551, doi. 10.1007/s13555-021-00570-4
- By:
- Publication type:
- Article
Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses.
- Published in:
- Dermatology & Therapy, 2021, v. 11, n. 1, p. 73, doi. 10.1007/s13555-019-00337-y
- By:
- Publication type:
- Article
Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque Psoriasis.
- Published in:
- Dermatology & Therapy, 2020, v. 10, n. 6, p. 1255, doi. 10.1007/s13555-020-00434-3
- By:
- Publication type:
- Article
Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses.
- Published in:
- Dermatology & Therapy, 2020, v. 10, n. 1, p. 73, doi. 10.1007/s13555-019-00337-y
- By:
- Publication type:
- Article
The Potential Benefits of Certolizumab Pegol in Patients with Concurrent Psoriatic Arthritis and Chronic Plaque Psoriasis: A Case Series and Review of the Literature.
- Published in:
- Dermatology & Therapy, 2019, v. 9, n. 2, p. 373, doi. 10.1007/s13555-019-0290-5
- By:
- Publication type:
- Article
Clinical course, treatment and management of generalised pustular psoriasis from a United Kingdom extension of a global Delphi panel.
- Published in:
- Skin Health & Disease, 2024, v. 4, n. 3, p. 1, doi. 10.1002/ski2.359
- By:
- Publication type:
- Article
Functional Genomics and Insights into the Pathogenesis and Treatment of Psoriasis.
- Published in:
- Biomolecules (2218-273X), 2024, v. 14, n. 5, p. 548, doi. 10.3390/biom14050548
- By:
- Publication type:
- Article
Epidermal growth factor receptor/mitogen-activated kinase inhibitor treatment induces a distinct inflammatory hair follicle response that includes collapse of immune privilege.
- Published in:
- British Journal of Dermatology, 2024, v. 191, n. 5, p. 791, doi. 10.1093/bjd/ljae243
- By:
- Publication type:
- Article
Prevalence, incidence, mortality and healthcare resource use for generalized pustular psoriasis, palmoplantar pustulosis and plaque psoriasis in England: a population-based cohort study.
- Published in:
- British Journal of Dermatology, 2024, v. 191, n. 4, p. 529, doi. 10.1093/bjd/ljae217
- By:
- Publication type:
- Article
653 - Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema: pooled results of the phase 3 DELTA-1 and -2 trials.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.032
- By:
- Publication type:
- Article
680 - Efficacy of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis by age of onset: analysis of two phase 3 clinical trials.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.054
- By:
- Publication type:
- Article
649 - Safety of tralokinumab for the treatment of atopic dermatitis in patients with up to 4.5 years of treatment: an updated integrated analysis of eight clinical trials.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.028
- By:
- Publication type:
- Article
655 - Long-term safety and efficacy of delgocitinib cream for up to 36 weeks in adults with chronic hand eczema: results of the phase 3 open-label extension DELTA-3 trial.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.034
- By:
- Publication type:
- Article
619 - Lebrikizumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients not adequately controlled or non-eligible for cyclosporine: a placebo-controlled, randomized phase 3 clinical study (ADvantage).
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.005
- By:
- Publication type:
- Article
The use of serum methotrexate level as an assessment of biochemical drug adherence in psoriasis.
- Published in:
- British Journal of Dermatology, 2024, v. 190, n. 6, p. 927, doi. 10.1093/bjd/ljae096
- By:
- Publication type:
- Article
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials.
- Published in:
- British Journal of Dermatology, 2024, v. 190, n. 5, p. 668, doi. 10.1093/bjd/ljae014
- By:
- Publication type:
- Article
The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
- Published in:
- British Journal of Dermatology, 2024, v. 190, n. 5, p. 689, doi. 10.1093/bjd/ljad481
- By:
- Publication type:
- Article
Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies.
- Published in:
- British Journal of Dermatology, 2024, v. 190, n. 4, p. 559, doi. 10.1093/bjd/ljad430
- By:
- Publication type:
- Article
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.
- Published in:
- British Journal of Dermatology, 2024, v. 190, n. 4, p. 477, doi. 10.1093/bjd/ljad429
- By:
- Publication type:
- Article
Characteristics of 'super responders' and 'super nonresponders' to first biologic monotherapy for psoriasis: a nested case–control study.
- Published in:
- British Journal of Dermatology, 2024, v. 190, n. 3, p. 441, doi. 10.1093/bjd/ljad446
- By:
- Publication type:
- Article